Suchergebnisse - "Wei, Ying"

PubPharm (12)

1

SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson's disease

enthalten in: Acta pharmacologica Sinica | 2024

von Yu, W. | Wang, L. | Ren, W. | +7

2

Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma

enthalten in: Acta pharmacologica Sinica | 2023

von Zhang, L. | Li, X. | Shi, X. | +10

3

The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth

enthalten in: Acta pharmacologica Sinica | 2022

von Xu, F. | Sun, H. | Fang, R. | +10

4

Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells

enthalten in: Acta pharmacologica Sinica | 2021

von Zhang, B. | Chen, X. | Fan, X. | +7

5

Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer

enthalten in: Acta pharmacologica Sinica | 2019

von Liu, B. | Wang, T. | Li, L. | +9

6

Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism

enthalten in: Acta pharmacologica Sinica | 2019

von Liu, Y. | Feng, J. | Sun, M. | +8

7

The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways

enthalten in: Acta pharmacologica Sinica | 2018

von Li, H. | Wang, Z. | Jiang, M. | +9

8

A mutant of HBx (HBxDelta127) promotes hepatoma cell growth via sterol regulatory element binding protein 1c involving 5-lipoxygenase

enthalten in: Acta pharmacologica Sinica | 2010

von Wang, Q. | Zhang, W. | Ye, L. | +1

9

Transformation of human liver L-O2 cells mediated by stable HBx transfection

enthalten in: Acta pharmacologica Sinica | 2009

von Zhang, W. | Cai, N. | Ye, L. | +1

10

Gene expression profiles of human liver cells mediated by hepatitis B virus X protein

enthalten in: Acta pharmacologica Sinica | 2009

von Zhang, W. | Xu, F. | Shan, C. | +3